| Nooruddin S Punjwani, MD | |
|
515 Olmstead Park Dr, Sugar Land, TX 77479-4424 | |
| (303) 933-8270 | |
| Not Available |
| Full Name | Nooruddin S Punjwani |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 28 Years |
| Location | 515 Olmstead Park Dr, Sugar Land, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053367649 | NPI | - | NPPES |
| 311320099 | Medicaid | ME | |
| 023186 | Other | ANTHEM BCBS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wyandot Memorial Hospital | Upper sandusky, OH | Hospital |
| Marietta Memorial Hospital | Marietta, OH | Hospital |
| Avita Ontario | Ontario, OH | Hospital |
| Memorial Hermann Memorial City Hospital | Houston, TX | Hospital |
| Knox Community Hospital | Mount vernon, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Miguel Oneto, Md, Pa | 3476677600 | 7 |
| Singleton Associates Pa | 6305731118 | 691 |
| Memorial Mri And Diagnostic Llc | 6507859568 | 31 |
| Riverside Radiology And Interventional Associates Inc | 8729976964 | 206 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | Texas Tech University Health Sciences Center El Paso |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598705055 PECOS PAC ID: 7517864754 Enrollment ID: O20031216000806 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | Singleton Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538107875 PECOS PAC ID: 6305731118 Enrollment ID: O20040315000385 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | Memorial Mri And Diagnostic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912989120 PECOS PAC ID: 6507859568 Enrollment ID: O20051209000488 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | Unicare Mri & Diagnostic Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598896516 PECOS PAC ID: 9032200720 Enrollment ID: O20070809000590 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | North Star Mri Of Frisco Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649356759 PECOS PAC ID: 2769574854 Enrollment ID: O20070821000328 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | North Star Diagnostic Imaging, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467787739 PECOS PAC ID: 8729118021 Enrollment ID: O20100614000182 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | Miguel Oneto, Md, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669786950 PECOS PAC ID: 3476677600 Enrollment ID: O20100825000396 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | North Star Mri Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033174701 PECOS PAC ID: 5890762330 Enrollment ID: O20110524000030 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | North Star Mcd, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063712461 PECOS PAC ID: 2668659434 Enrollment ID: O20110602000702 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | North Star Fm Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174812028 PECOS PAC ID: 1153591763 Enrollment ID: O20110908001884 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | North Star Cn Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013305945 PECOS PAC ID: 0547589376 Enrollment ID: O20150429001555 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | North Star Fp Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033630835 PECOS PAC ID: 6800168576 Enrollment ID: O20170816002017 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | North Star Gv Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922512664 PECOS PAC ID: 0648539023 Enrollment ID: O20180110000546 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | Riverside Radiology And Interventional Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093718496 PECOS PAC ID: 8729976964 Enrollment ID: O20181203000880 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | Grandview Radiology Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922066836 PECOS PAC ID: 8325946726 Enrollment ID: O20230712000283 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Entity Name | Saint Vincent Radiological Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366482093 PECOS PAC ID: 1850365578 Enrollment ID: O20240215000530 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nooruddin S Punjwani, MD 2201 N Central Expy Ste 185, Richardson, TX 75080-2763 Ph: (303) 933-8270 | Nooruddin S Punjwani, MD 515 Olmstead Park Dr, Sugar Land, TX 77479-4424 Ph: (303) 933-8270 |
News Archive
Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.
Tweaking a specific cell type's ability to absorb potassium in the brain improved walking and prolonged survival in a mouse model of Huntington's disease, reports a UCLA study published March 30 in the online edition of Nature Neuroscience. The discovery could point to new drug targets for treating the devastating disease, which strikes one in every 20,000 Americans.
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.
The next two weeks of a health reform fight may prove pivotal for President Barack Obama's image and his ability to use his popularity to get things done, The Washington Post reports.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.
› Verified 2 days ago
Megan Jenkins Kalambo, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 17510 W Grand Pkwy S, Sutie 120, Sugar Land, TX 77479 Phone: 713-745-4555 Fax: 713-563-9779 | |
Yuxuan Lin, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5231 Fountainbrook Ln, Sugar Land, TX 77479 Phone: 713-443-8571 | |
Dr. Carlos R Hamilton Iii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4690 Sweetwater Blvd, Suite 200, Sugar Land, TX 77479 Phone: 281-565-0033 Fax: 281-565-0568 | |
Puneet Ghei, MD Radiology Medicare: Medicare Enrolled Practice Location: 1435 Highway 6 Ste 102, Sugar Land, TX 77478 Phone: 281-313-1700 Fax: 281-313-1705 | |
Judson Horace Snow Jr., M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 17500 W Grand Pkwy, Sugar Land, TX 77479 Phone: 713-481-3533 Fax: 713-432-0221 | |
Dr. John H. Fischer Ii, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4690 Sweetwater Blvd Ste 200, Sugar Land, TX 77479 Phone: 281-565-0033 Fax: 281-565-0568 |